Skip to main content

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Publication ,  Journal Article
Huarte, E; Cubillos-Ruiz, JR; Nesbeth, YC; Scarlett, UK; Martinez, DG; Buckanovich, RJ; Benencia, F; Stan, RV; Keler, T; Sarobe, P; Sentman, CL ...
Published in: Cancer Res
September 15, 2008

Dendritic cells (DC) and cytokines that expand myeloid progenitors are widely used to treat cancer. Here, we show that CD11c(+)DEC205(+) DCs coexpressing alpha-smooth muscle actin and VE-cadherin home to perivascular areas in the ovarian cancer microenvironment and are required for the maintenance of tumor vasculature. Consequently, depletion of DCs in mice bearing established ovarian cancer by targeting different specific markers significantly delays tumor growth and enhances the effect of standard chemotherapies. Tumor growth restriction was associated with vascular apoptosis after DC ablation followed by necrosis, which triggered an antitumor immunogenic boost. Our findings provide a mechanistic rationale for selectively eliminating tumor-associated leukocytes to promote antitumor immunity while impeding tumor vascularization and to develop more effective DC vaccines based on a better understanding of the tumor microenvironment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Res

DOI

EISSN

1538-7445

Publication Date

September 15, 2008

Volume

68

Issue

18

Start / End Page

7684 / 7691

Location

United States

Related Subject Headings

  • T-Lymphocytes, Cytotoxic
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Necrosis
  • Mice
  • Humans
  • Female
  • Disease Progression
  • Dendritic Cells
  • Cell Growth Processes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Huarte, E., Cubillos-Ruiz, J. R., Nesbeth, Y. C., Scarlett, U. K., Martinez, D. G., Buckanovich, R. J., … Conejo-Garcia, J. R. (2008). Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res, 68(18), 7684–7691. https://doi.org/10.1158/0008-5472.CAN-08-1167
Huarte, Eduardo, Juan R. Cubillos-Ruiz, Yolanda C. Nesbeth, Uciane K. Scarlett, Diana G. Martinez, Ronald J. Buckanovich, Fabian Benencia, et al. “Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.Cancer Res 68, no. 18 (September 15, 2008): 7684–91. https://doi.org/10.1158/0008-5472.CAN-08-1167.
Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res. 2008 Sep 15;68(18):7684–91.
Huarte, Eduardo, et al. “Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.Cancer Res, vol. 68, no. 18, Sept. 2008, pp. 7684–91. Pubmed, doi:10.1158/0008-5472.CAN-08-1167.
Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res. 2008 Sep 15;68(18):7684–7691.

Published In

Cancer Res

DOI

EISSN

1538-7445

Publication Date

September 15, 2008

Volume

68

Issue

18

Start / End Page

7684 / 7691

Location

United States

Related Subject Headings

  • T-Lymphocytes, Cytotoxic
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Necrosis
  • Mice
  • Humans
  • Female
  • Disease Progression
  • Dendritic Cells
  • Cell Growth Processes